TABLE 3.

Antibiotic resistance patterns of the ST65 clone and its passage^a

Antibiotic	AST data for (mg/L):
	P1	PEKP4222	P6	PEKP4130	B3	PEKP3083	PEKP3048	PEKP123	A7	J4	10th passage–P1	10th passage–PEKP4222
Ticarcillin/clavulanate	≥128	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≥128	≤8
Piperacillin/tazobactam	≥128	8	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≥128	8
Ceftazidime	≥64	0.5	≤0.12	0.25	≤0.12	≤0.12	≤0.12	0.25	≤0.12	≤0.12	≥64	0.5
Cefoperazone/sulbactam	≥64	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≤8	≥64	≤8
Cefepime	≥32	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≥32	≤0.12
Aztreonam	≥64	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≥64	≤1
Imipenem	≥16	≤0.25	≤0.25	≤0.25	≤0.25	0.5	0.5	≤0.25	0.5	≤0.25	≥16	0.5
Meropenem	≥16	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≥16	≤0.25
Amikacin	≥64	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≤2	≥64	≤2
Tobramycin	≥16	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≥16	≤1
Ciprofloxacin	≥4	2	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≥4	2
Levofloxacin	≥8	4	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≥8	4
Doxycycline	≥16	≥16	1	1	1	1	1	1	1	1	≥16	≥16
Minocycline	8	≥16	≤1	≤1	≤1	≤1	≤1	2	≤1	≤1	≥16	≥16
Tigecycline	2	≥8	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	1	≤0.5	≤0.5	2	≥8
Trimethoprim/sulfamethoxazole	40	≥320	≤20	≤20	≤20	≤20	≤20	≤20	≤20	≤20	40	≥320
Ceftazidime/avibactamb	22	27	27	29	28	28	26	25	26	26	21	21
Cefiderocolb	22	28	27	27	27	27	28	26	24	26	21	27

^aAST was conducted using the K-B method.